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Abstract
Background The apparent diffusion coefficient (ADC) is po-
tentially useful for assessing treatment response in
nephroblastoma (Wilms tumour). However the precision of
ADC measurements in these heterogeneous lesions is
unknown.
Objective To assess intra- and interobserver variability of
whole-tumour ADC measurements in viable parts of
nephroblastomas at diagnosis and after preoperative
chemotherapy.
Materials and methods We included children with histopath-
ologically proven nephroblastoma who had undergone MRI
with diffusion-weighted imaging before and after preoperative
chemotherapy. Three independent observers performed
whole-tumour ADC measurements of all lesions, excluding
non-enhancing areas. One observer evaluated all lesions on
two occasions. We performed analyses using Bland–Altman
plots and concordance correlation coefficient (CCC) calcula-
tions with 95% limits of agreement for median ADC, differ-
ence between pre- and post-chemotherapy median ADC
(ADC shift) and percentage of pixels with ADC values
<1.0×10−3 mm2/s.
Results In 22 lesions (13 pretreatment and 9 post-treatment) in
10 children the interobserver variability in median ADC and
ADC shift were within the interval of approximately ±0.1×
10−3 mm2/s (limits of agreement for median ADC ranged
−0.08–0.11×10−3 mm2/s and for ADC-shift −0.11–0.09×
10−3 mm2/s). The interobserver variability for percentage of
low-ADC pixels was larger and also biased. The calculated
CCC confirmed good intra- and interobserver agreement (ρ-c
ranging from 0.968 to 0.996).
Conclusion Measurements of whole-tumour ADC values ex-
cluding necrotic areas seem to be sufficiently precise for de-
tection of chemotherapy-related change.
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Introduction
The monitoring of oncological treatment response with cross-
sectional imaging is traditionally based on tumour size assess-
ment, but change in size does not always correspond to actual
biological response [1–3]. Increase in volume can occur in
well-responding tumours, e.g., during differentiation. On the
other hand, tumours that shrink may still contain considerable
volumes of viable tumour, e.g., blastema and anaplastic ele-
ments of nephroblastoma. Therefore, imaging parameters be-
yond those that estimate overall tumour volume are desirable.
MRI is the preferred modality for imaging renal tumours in
children because it provides high soft-tissue contrast and of-
fers anatomical and quantitative information without the use
of ionising radiation [4, 5]. Diffusion-weighted MRI (DWI)
measures random motion of water protons that is restricted in,
for instance, highly cellular lesions. The apparent diffusion
coefficient (ADC) is a quantification of the degree of impeded
water motion. Hence, it can be utilised as a noninvasive
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in vivo biomarker. A decrease in cellularity, a common histo-
pathological treatment response, might be detected as in-
creased apparent diffusion at DWI [6]. Specifically, reports
in nephroblastoma have suggested that there is a shift towards
higher ADC values in tumours that have responded to preop-
erative chemotherapy.
Unfortunately there is considerable heterogeneity in report-
ed acquisition techniques and methods of ADCmeasurements
[7], and the variability in measurements is not known. In other
words, we do not know whether an observed change in ADC
truly reflects a biological process rather than a random mea-
surement error. An important step in exploring this is to esti-
mate the variability caused by imaging readers.
Our aim was therefore to quantify the variability among
experienced readers and also between reading sessions, using
already proposed parameters of the tumour volume ADC dis-
tribution: the median ADC at a single scan, and the difference
in median ADC between the pre-and post-chemotherapy
scans. Because low ADC is associated with high cellularity
[7], we also explored the variability in assessment of the per-
centage of voxels within tumour with low ADC values.
Materials and methods
Patients
The research ethics committee of our institution waived the
need for ethics approval for this retrospective review. We in-
cluded 10 consecutive children referred to our tertiary care
paediatric hospital during July 2012–July 2013. All had his-
topathologically proven nephroblastoma. MRI is the modality
of choice for formal cross-sectional tumour imaging at our
institution and was performed as part of standard clinical care
at initial presentation and after preoperative chemotherapy.
Exclusion criteria were incomplete MRI study, predominantly
cystic lesions, lesions where the largest area on a single slice
was <3 cm2 or lesionswith a total volume of <6 cm3. In smaller
lesions there is a considerable risk for partial volume effects.
All children were treated according to the guidelines of the
International Society of Paediatric Oncology (SIOP-RT
2001) [8]: 4 weeks’ pre-operative chemotherapy with vincris-
tine and actinomycin D is considered standard therapy for
localised tumours. Children with metastases at diagnosis re-
ceive 6 weeks of preoperative therapy with three drugs, includ-
ing doxorubicin [8].
Magnetic resonance imaging acquisition
Contrast-enhanced MRI of the abdomen including DWI was
performed on a 1.5-T scanner (Avanto; Siemens Healthcare,
Erlangen, Germany). The imaging protocol consisted of fat-
suppressed axial pre- and post-gadolinium T1-W turbo spin-
echo, axial and coronal T2-W short tau inversion recovery,
and diffusion-weighted imaging (Table 1). Diffusion-
weighted sequences were acquired in the axial plane during
free-breathing, applying b values of at least 0 s/mm2, 50 s/
mm2, 250 s/mm2, 500 s/mm2 and 1,000 s/mm2 (Table 1).
ADC maps were automatically generated by the MRI mea-
surement system.
Table 1 Scan parameters at 1.5-T MRI for suspected renal tumour or for imaging of nephroblastoma after neo-adjuvant chemotherapy
Parameter T2 STIR T2 SPACE DWI T1 pre/post T1 pre/post
Pulse sequence 2-Ds short tau inversion
recovery (STIR)
spin echo






2-D turbo spin echo
with fat-suppression




Repetition time (ms) >6,000 >2,000 2,700 400–670 590
Echo time (ms) 62 238 90 17–20 23
Inversion time (ms) 130
Slice orientation Coronal and axial Axial Axial Axial Axial
Slice thickness (mm) 5–6 0.9 6 5–6 7
Slice gap (mm) 0–0.5 0 1.8–2.4 1–3 1.4
Echotrain length 21 89 1 1 9
Acquisition matrix 256×194 256×255 128×96 256×154 192×192
Receive bandwidth
(Hz/pixel)
200 651 1,500 70 300
b values (s/mm2) – – At least 0, 50, 100,
250, 500, 1,000
– –
DWI diffusion-weighted imaging, Post post-treatment, Pre pretreatment, SPACE sampling perfection with application of optimized contrasts using
different flip angle evolution, STIR short tau inversion recovery
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Children were awake, sedated or under general anaesthesia,
depending on their ability to cooperate. Gadoterate
meglumine (Dotarem; Guerbet Laboratories, Roissy, France)
was administered at an intravenous dose of 0.05 mmol/kg
bodyweight. All children were screened for contraindications,
such as risk factors for nephrogenic systemic fibrosis. Estima-
tion of glomerular filtration rate was performed in children
with suspicion of renal disease and after chemotherapy. All
children received the intravenous spasmolytic hyoscine
butylbromide (Buscopan; Boehringer Ingelheim Limited,
Bracknell, UK) at a dose of 0.4 mg/kg body weight to reduce
artefacts caused by peristaltic movements of the bowel.
Image analysis
The anonymised MRI datasets including the ADC maps were
transferred to the DICOM software OsiriX version 5.5.2
(Pixmeo SARL, Bernex, Switzerland). Three independent
paediatric radiologists (Ø.E.O, P.D.H and A.S.L, with 14, 10
and 5 years of experience with paediatric abdominal MRI,
respectively) performed the ADC measurements. The readers
were blinded to one another’s results and to histopathology
reports. The pretreatment images were available for review
during analysis of the post-treatment datasets. To assess the
intra-observer variability, one reader (A.S.L.) obtained the
measurements twice, with a minimum interval of 4 weeks.
The first reading of this reviewer was used to assess the inter-
observer variability.
Whole-tumour ADC measurement protocol
Regions of interest (ROIs) were drawn manually on the
ADC maps. This was done by each reader for interobserver
analysis, and at both readings for intra-observer analysis.
Conventional MR images guided the definition of the out-
line of the tumour at each consecutive tumour-containing
slice, excluding peritumoural oedema. To minimise the
partial volume effect, we only included the sections where
the tumor area was >50% of the adjacent more central slice
and where the tumor area was at least 3 cm2. We used the
pre- and post-gadolinium T1-W images to create a mask
that excluded areas of tumour with no or very low en-
hancement, because these were thought to represent necro-
sis, haemorrhage or cystic elements. Therefore, we
subtracted the pre- from the post-gadolinium T1-W im-
ages. We resampled this subtracted dataset against the tu-
mour ADC dataset to obtain similar voxel size and orien-
tation. Further analysis was performed with the image-
processing program ImageJ, version 1.47 (National Insti-
tutes of Health, Bethesda, MD). The pixels of the
subtracted dataset with an enhancement at or above that
of the erector spinae muscles were used as a threshold
filter for the ADC dataset. The final ADC dataset therefore
represented all pixels from the enhancing parts of the tu-
mour. These whole-tumour ADC sets were exported for
statistical analysis. The requisite of including only the vi-
able parts of the tumour in the analysis of ADC distribu-
tion is exemplified in Fig. 1.
Because not all whole-tumour ADC histograms were
normally distributed, the median ADC was chosen to rep-
resent the central location of the ADC distribution. Mea-
suring only a mean or median could conceal relevant in-
formation. Therefore we also assessed the variability with-
in and between observers for percentage of pixels with low
ADC (<1.00×10−3 mm2/s), assuming that lower ADC
values are more relevant in assessing treatment response
[8, 9]. Last, we assessed the variability in measurements
for the difference in median ADC before and after neo-
adjuvant chemotherapy.
Statistical analysis
Intra- and interobserver variability for the three variables (me-
dian ADC, percentage of low-ADC pixels, and shift in median
ADC during chemotherapy) were analysed according to the
method of Bland and Altman with calculation of the 95%
limits of agreement [10].
Additionally, the Lin [11] concordance correlation coeffi-
cient (CCC) was calculated along with the 95% confidence
intervals as another measure of assessing the observer
variability.
The Wilcoxon rank sum test was used to compare the
pre- and post-treatment median ADC differences for every
rater pair to check for potentially significant differences,
i.e. rater variability, in pre- and post-treatment lesions.
Spearman’s rho was used for assessing any linear relation
between the average and the differences for the tested ADC
parameters. P-values <0.05 were considered statistically
significant.
R software (version 3.0.1; R Foundation for Statistical
Computing, Vienna, Austria) was used for calculation of the
concordance correlation coefficient. All other statistical anal-
yses were executed using Statistical Package for the Social
Sciences (version 22.0; IBM, Armonk, NY).
Results
Patients
We included 10 children (mean age 2.7 years, range 0.5–
4.5 years). They had a total of 15 histologically proven
nephroblastoma lesions. Two lesions were excluded from
analysis because of their predominantly cystic nature
(Table 2). In 9 of 10 children, complete MRI studies after
preoperative therapy were available for analysis. Two
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Fig. 1 MR images in a 2-year-old girl with left-side nephroblastoma
illustrate the importance of including only the viable parts of the
tumour in the analysis of ADC distribution. a Axial T2-SPACE, (b)
axial T1-W turbo spin echo and (c) subtracted post-contrast axial T1-W
MR images show a large heterogeneous tumour (arrows) with
haemorrhagic and necrotic components arising from the left kidney,
consistent with nephroblastoma. d–f Axial diffusion-weighted images
with b values of 0 (d) and 1,000 (e) and the ADC map (f) illustrate the
low signal and low ADC within the large necrotic/haemorrhagic
components (arrowheads). g, h The whole-tumour ADC histograms
(horizontal axis: ADC value [10−3 mm2/s]) without subtraction (g) and
with subtraction (h) demonstrate the need for excluding the less-
enhancing parts of the tumour for ADC analysis. Because of the
haemorrhagic/necrotic components within the tumour, the histogram
without subtraction shows a high peak ADC value of about 0. This is
probably related to susceptibility artefacts and results in incorrect ADC
calculations that can skew the median ADC value to a lower value. ADC
apparent diffusion coefficient, SPACE sampling perfection with
application of optimized contrasts using different flip angle evolution
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additional post-treatment lesions were excluded for the fol-
lowing reasons: too small (n=1, volume 5.5 cm3), predomi-
nantly cystic (n=1). In total we included 13 pre-treatment
(mean volume 323.0 cm3, range 7.4–1,157.8 cm3) and 9
post-treatment (mean volume 225.3 cm3, range 6.2–1,
208.1 cm3) lesions for final analysis. The flow diagram of
standards for reporting diagnostic accuracy studies
(STARD) is illustrated in Fig. 2.
Intra-observer variability
The intra-observer variability for whole-tumour ADC
measurements is displayed in Figs. 3, 4 and 5. The
Bland–Altman plot for median ADC demonstrates narrow
limits of agreement (mean difference: 0; 95% limits of
agreement: −0.06–0.06×10−3 mm2/s) indicating very low
intra-observer variability. There was no striking trend to
suggest a bias in the variability. One outlier represents a
post-treatment lesion with haemorrhagic changes. The
intra-observer variability was not significantly different
for pre- or post-chemotherapy measurements (P=0.31).
The concordance correlation coefficient (ρ-c=0.994 for
median ADC; ρ-c=0.995 for post-treatment minus pre-
treatment median ADC; ρ-c=0.996 for % low-ADC
pixels) indicated very good agreement for all three tested
parameters (Table 3).
Table 2 Patient characteristics















Fig. 2 Flow diagram according
to standard of reporting
diagnostic accuracy studies
(STARD). *One child with
bilateral disease underwent
primary resection of one lesion
and preoperative treatment for the
contralateral lesion
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Interobserver variability
For median ADC (Fig. 3) the limits of agreement were narrow
for all three reader pairs, indicating low interobserver variabil-
ity (ranging −0.08–0.11×10−3 mm2/s). The average difference
was close to zero and there was no suggestion of any bias in
the variability, i.e. the variability was comparable between
tumours with high and low ADC values.
For percentage of low-ADC pixels, Bland–Altman plots
showed wider limits of agreement (−15.9–12.9%) with a trend
towards negative differences between readers 2 and 3 and
readers 1 and 3, indicating that reader 3 measured a higher
percentage of low pixels in tumours with predominantly low
ADC (Fig. 4). This linear relation was confirmed by a
Spearman’s rho of −0.53 (P=0.01) for readers 1 and 3 and
Spearman’s rho of −0.66 (P=0.01) for readers 2 and 3, indi-
cating a negative relation between the mean ADC and the
differences between the readers, suggesting a systematic error.
For the difference in median ADC before and after pre-
operative therapy (Fig. 5), the limits of agreement ranged
−0.11–0.09×10−3 mm2/s, indicating reasonably good interob-
server agreement. The average difference was close to zero,
and there was no suggestion of any bias in the variability.
The calculated correlation coefficient for all three parame-
ters indicated good agreement for all tested parameters
(Table 3).
The Wilcoxon rank sum test showed no statistically signif-
icant difference in inter-rater variability for pre- and post-
Fig. 3 Median intra- and interobserver variability for whole-tumour
apparent diffusion coefficient (ADC) measurements. a–d Bland–
Altman plots show median ADC values for intra-observer variability
(a), for observers 1 and 2 (b), for observers 2 and 3 (c) and for
observers 1 and 3 (d). X-axis shows the average of the two readings,
whereas the y-axis represents the difference between the readings. The
solid lines represent the average absolute difference between the two
readings. The dashed lines represent the 95% confidence intervals of
the average differences (limits of agreement). The grey circles represent
the measurements of the lesions before treatment; the black triangles
represent the measurements of the post-treatment lesions. The Bland–
Altman plots show narrow limits of agreement and somewhat larger
disagreement at higher ADC values, but no definite bias. The outlier
(patient 10, with average of readings of 1.45×10−3 mm2/s) in the intra-
observer plot (a) was probably related to post-treatment haemorrhagic/
necrotic changes. The outliers (patient 22, 1.25×10−3 mm2/s) in (c) and
(d) represent measurements of the same relatively small lesion (7 cm3),
which was difficult to discern from the surrounding renal tissue
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treatment lesions (raters 1 and 2: P=0.21; raters 2 and 3: P=
0.51; raters 1 and 3: P=0.77).
The outliers represent either small lesions or lesions with
relatively large haemorrhagic/necrotic or cystic components
(Table 4). The outliers in all three intra-observer plots repre-
sent measurements of a single lesion that demonstrated
haemorrhagic/necrotic changes after treatment. The outliers
for the interobserver readings were almost all related to the
relatively small size of the lesions.
Discussion
Our results show reasonably good intra- and interobserver
agreement for whole-tumour median ADC and for
chemotherapy-induced shift in median ADC. However, the
estimates of percentage of low-ADC pixels seemed less reli-
able because the limits of agreement were wider and because
there was an overall bias in the reader/reading differences. In
other words, the latter variable seemed more sensitive to the
definition of region of interest and the chosen threshold of
subtraction, resulting in a wider 95% limit of agreement for
all rater pairs. The percentage of low-ADC pixels, therefore,
seems to be an inferior variable that we will not discuss
further.
What is acceptable variability depends on the clinical ap-
plication, the range of the true values and the degree of clin-
ically relevant change in ADC measurements. McDonald
et al. [12] reported a change in ADC values in six patients
with nephroblastoma varying from 0.03×10−3 mm2/s to
Fig. 4 Intra- and interobserver variability for whole-tumour apparent
diffusion coefficient (ADC) measurements. a–d Bland–Altman plots
show the percentage of pixels below 1.00×10−3 mm2/s for intra-
observer variability (a), for observers 1 and 2 (b), for observers 2 and 3
(c) and for observers 1 and 3 (d). The grey circles represent the
measurements of the pretreatment lesions; the black triangles represent
the measurements of the post-treatment lesions. The wide limits and the
possible trend suggest that the percentage of low pixel measurements is a
less-reliable measurement. a The outlier (patient 10, with average of
readings of 17.6%) in the intra-observer plot is probably related to post-
treatment haemorrhagic/necrotic changes. b, d The outliers (patient 54,
average percentage of readings about 55%) represent a relatively small
(6 cm3) post-treatment lesion. c The outlier (patient 22, average
percentage of readings 12%) represents a relatively small lesion (7 cm3)
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0.81×10−3 mm2/s. Interestingly, those with necrosis or
stromal differentiation all had an ADC shift of more than
0.14×10−3 mm2/s. We found that differences of approximate-
ly 0.10×10−3 mm2/s or more were reliably identified. This
implies that ADC shifts reported by McDonald et al. [12] in
regressing or stromally differentiating nephroblastoma are
likely to be reliably identified. On the other hand, the reported
ADC shift in nephroblastomas that respond with epithelial
differentiation (≤0.08×10−3 mm2/s) is in the range of mea-
surement error.
To our knowledge this is a unique study reporting reliabil-
ity in ADC-distribution parameters in enhancing parts of
nephroblastomas. Previous studies have highlighted the im-
proved inter-rater variability for the whole-lesion ADC mea-
surements for assessing the central value of the ADC distribu-
tion in different kinds of tumours [13–15]. Single-slice or
sample ROI measurements are probably suboptimal in
nephroblastoma because of the heterogeneity of these tu-
mours, i.e. variable fractions of blastemal, epithelial and stro-
mal cells. Under-sampling could conceal information that is
important for response prediction and assessment [1, 16]. The
second important component of our proposed method is the
exclusion from ADC analysis all areas with little or absent
gadolinium enhancement. Although the presence and extent
of necrosis could serve as a biomarker for prediction and re-
sponse assessment, in our experience necrotic areas in
nephroblastomas sometimes demonstrate very low ADC
values, mimicking highly cellular portions of the lesion. A
possible explanation for low ADC in necrotic areas may be
the pattern of chemotherapy-induced change described at his-
topathology, including coagulative-type necrosis, fibrosis,
hemosiderin-laden macrophages and haemorrhage [17]. The-
se haemorrhagic components result in susceptibility artefacts
and incorrect ADC calculations that skew the ADC median
Fig. 5 Intra- and interobserver variability for whole-tumour
measurements of apparent diffusion coefficient (ADC) shift from
pretreatment to post-treatment. a–d Bland–Altman plots show post-
treatment median ADC minus pretreatment median ADC for intra-
observer variability (a), for observers 1 and 2 (b), for observers 2 and 3
(c) and for observers 1 and 3 (d). a The outlier in the intra-observer plot
represents the lesion with post-treatment changes as previously described
(patient 10, average of readings of 0.77×10−3 mm2/s). The single outlier
for the inter-observer analyses represents a relatively small lesion (patient
22, volume 7 cm3, average of readings of 0.22×10−3 mm2/s)
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values to lower values. We do not claim that simple
thresholding provides a perfect mask for necrosis, but it is a
pragmatic and easily achievable method for reducing the in-
fluence on the central ADC parameter of extreme values with-
in necrotic regions. It may be argued that it is unjustified to
exclude intratumoural regions from analysis, and that this in-
troduces undesirable subjectivity to the analyses. However,
knowing whether the ADC values within a cystic or necrotic
component are high or low does not add diagnostic value.
Our retrospective study has several limitations. First, the
number of subjects and number of lesions were limited,
reflecting the low incidence of this tumour. Second, small
and predominantly cystic tumours were excluded from fi-
nal analysis . However, in daily clinical practise
nephroblastomas are generally large lesions at presenta-
tion, and the solid components are the areas of interest
for response prediction and assessment. Third, our pro-
posed approach of whole-tumour ADC assessment is more
time-consuming compared to the single-slice or sample
ROI measurements that are quick and easy to perform. In
addition, our method of measurements could be more high-
ly influenced by the skills of the reader because several
successive steps are required in our technique. However
our results show good intra- and inter-rater variability.
Fourth, we used the enhancement of erector spinae muscles
as a threshold filter for excluding less-enhancing portions
of the lesions. Formal perfusion analysis to appoint the
subtraction threshold could further improve the selection
of viable areas of the lesions. However, potential mismatch
caused by slight movement between the diffusion, pre- and
post-contrast acquisitions is difficult to resolve. Last, the
degree of interobserver variability in measuring percentage
of low ADC is not independent of the chosen threshold.
However, some threshold had to be determined, and based
on our experience we chose the threshold of 1.00×
10−3 mm2/s [12].
Table 4 Characteristics of outliers identified in the intra- and interobserver variability analyses
Outlier Comparison of interest Patient number, pre/post treatment Possible cause(s) for high variability
1 Intra, median ADC 10, post Haemorrhagic/necrotic components
2 Inter, median ADC, readers 2 and 3 22, pre Small (7 cm3), difficult to discern from normal renal tissue
3 Inter, median ADC, readers 2 and 3 8, pre Cystic components (volume 17 cm3)
4 Inter, median ADC, readers 1 and 3 22, pre Small (7 cm3)
5 Intra, post minus pre 10 Haemorrhagic/necrotic components post-treatment
6 Inter, post minus pre, readers 1 and 2 53 Post-chemotherapy lesion volume 8 cm3
7 Intra, % low-ADC pixels 10, post Haemorrhagic/necrotic components
8 Inter, % low-ADC pixels, readers 1 and 2 54, post Small (6 cm3)
9 Inter, % low-ADC pixels, readers 2 and 3 22, pre Small (7 cm3)
10 Inter, % low-ADC pixels, readers 1 and 3 54, post Small (6 cm3)
ADC apparent diffusion coefficient, Inter inter-rater, Intra intra-rater, Post post-treatment, Pre pretreatment
Table 3 Concordance correlation
coefficient for all parameters in
intra- and interobserver variability
Parameter Coefficient of concordance 95% confidence interval
Intra-observer Median ADC 0.994 0.986–0.998
% low-ADC pixels 0.996 0.991–0.998
Post-pre ADC 0.995 0.980–0.999
Interobserver Median ADC, Observers 1-2 0.991 0.979–0.996
Median ADC, Observers 2, 3 0.984 0.963–0.993
Median ADC, Observers 1, 3 0.982 0.957–0.992
% low-ADC pixels, Observers 1, 2 0.986 0.966–0.993
% low-ADC pixels, Observers 2, 3 0.973 0.945–0.987
% low-ADC pixels, Observers 1, 3 0.968 0.931–0.985
Post-pre ADC, Observers 1, 2 0.995 0.980–0.999
Post-pre ADC, Observers 2, 3 0.990 0.959–0.998
Post-pre ADC, Observers 1, 3 0.993 0.971–0.998
ADC apparent diffusion coefficient, Post-pre post-treatment ADC values minus pretreatment values
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Conclusion
Estimation of the median of the ADC distribution in enhanc-
ing parts of nephroblastoma is reliable to within approximate-
ly 0.1×10−3 mm2/s. Chemotherapy-induced shifts in median
ADC of about 0.1×10−3 mm2/s or more are therefore unlikely
to be caused by random error. This is encouraging because
reported shifts in ADC values in regressive and stromally
differentiating nephroblastomas are larger than this threshold.
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